Bischoff H - Search Results

1

Increased platelet activation in young Zucker rats with impaired glucose tolerance is improved by acarbose.

Schäfer A, Widder J, Eigenthaler M, Bischoff H, Ertl G, Bauersachs J. Schäfer A, et al. Among authors: bischoff h. Thromb Haemost. 2004 Jul;92(1):97-103. doi: 10.1160/TH04-02-0118. Thromb Haemost. 2004. PMID: 15213850

2

Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose.

Frantz S, Calvillo L, Tillmanns J, Elbing I, Dienesch C, Bischoff H, Ertl G, Bauersachs J. Frantz S, et al. Among authors: bischoff h. FASEB J. 2005 Apr;19(6):591-3. doi: 10.1096/fj.04-2459fje. Epub 2005 Jan 25. FASEB J. 2005. PMID: 15671153

3

Early acarbose treatment ameliorates resistance of insulin-regulated GLUT4 trafficking in obese Zucker rats.

Ledwig D, Müller H, Bischoff H, Eckel J. Ledwig D, et al. Among authors: bischoff h. Eur J Pharmacol. 2002 Jun 7;445(1-2):141-8. doi: 10.1016/s0014-2999(02)01714-4. Eur J Pharmacol. 2002. PMID: 12065205

4

Pharmacology of alpha-glucosidase inhibition.

Bischoff H. Bischoff H. Eur J Clin Invest. 1994 Aug;24 Suppl 3:3-10. Eur J Clin Invest. 1994. PMID: 8001624 Review.

5

The mechanism of alpha-glucosidase inhibition in the management of diabetes.

Bischoff H. Bischoff H. Clin Invest Med. 1995 Aug;18(4):303-11. Clin Invest Med. 1995. PMID: 8549017 Review.

6

D-glucose combined chronic toxicity and carcinogenicity studies in Sprague-Dawley rats and Syrian golden hamsters.

Bomhard E, Bischoff H, Mager H, Krötlinger F, Schilde B. Bomhard E, et al. Among authors: bischoff h. Drug Chem Toxicol. 1998 Aug;21(3):329-53. doi: 10.3109/01480549809002209. Drug Chem Toxicol. 1998. PMID: 9706465

7

Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition.

Bischoff H, Angerbauer R, Boberg M, Petzinna D, Schmidt D, Steinke W, Thomas G. Bischoff H, et al. Atherosclerosis. 1998 Sep;139 Suppl 1:S7-13. doi: 10.1016/s0021-9150(98)00188-9. Atherosclerosis. 1998. PMID: 9811153 Review.

8

Preclinical and clinical pharmacology of cerivastatin.

Bischoff H, Heller AH. Bischoff H, et al. Am J Cardiol. 1998 Aug 27;82(4B):18J-25J. doi: 10.1016/s0002-9149(98)00433-0. Am J Cardiol. 1998. PMID: 9737642 Review.

9

Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor.

Bischoff H, Angerbauer R, Bender J, Bischoff E, Faggiotto A, Petzinna D, Pfitzner J, Porter MC, Schmidt D, Thomas G. Bischoff H, et al. Among authors: bischoff e. Atherosclerosis. 1997 Nov;135(1):119-30. doi: 10.1016/s0021-9150(97)00188-3. Atherosclerosis. 1997. PMID: 9395280

10

Cholesteryl ester transfer protein and its inhibition.

Weber O, Bischoff H, Schmeck C, Böttcher MF. Weber O, et al. Among authors: bischoff h. Cell Mol Life Sci. 2010 Sep;67(18):3139-49. doi: 10.1007/s00018-010-0418-3. Epub 2010 Jun 18. Cell Mol Life Sci. 2010. PMID: 20556633 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

199 results

Search Page

Filters